

Reference number
2079-A

## SPECIALTY GUIDELINE MANAGEMENT

### INLYTA (axitinib)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### A. FDA-Approved Indications

Inlyta is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

###### B. Compendial Uses

1. Relapsed or surgically unresectable stage IV renal cell carcinoma
2. Papillary, Hürthle cell, or follicular thyroid carcinoma

All other indications are considered experimental/investigational and are not a covered benefit.

##### II. CRITERIA FOR INITIAL APPROVAL

###### A. **Renal Cell Carcinoma**

Authorization of 12 months may be granted for treatment of relapsed, metastatic, or unresectable renal cell carcinoma.

###### B. **Papillary, Hürthle cell, or Follicular Thyroid Carcinoma**

Authorization of 12 months may be granted for treatment of papillary, Hürthle cell, or follicular thyroid carcinoma.

##### III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

##### IV. REFERENCES

1. Inlyta [package insert]. New York, NY: Pfizer Inc., August 2014.
2. The NCCN Drugs & Biologics Compendium® © 2018 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed May 09, 2018.
3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Kidney Cancer. Version 4.2018. Accessed May 09, 2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf).
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Thyroid Carcinoma. Version 4.2018. Accessed May 09, 2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf).

Reference number
2079-A